The Rheumatologist
COVID-19 News
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Systemic Lupus Erythematosus Resource Center
      • Rheumatoid Arthritis Resource Center
      • Gout Resource Center
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Anti-Drug Antibodies May Affect RA Treatment

Anti-Drug Antibodies May Affect RA Treatment

June 5, 2017 • By Lara C. Pullen, PhD

  • Tweet
  • Email
Print-Friendly Version / Save PDF

Physicians commonly prescribe different tumor necrosis factor (TNF) inhibitors to treat rheumatoid arthritis (RA). Etanercept is a soluble TNF receptor; whereas, adalimumab and infliximab are anti-TNF monoclonal antibodies. New research performed by Robert J. Moots, PhD, FRCP, a professor of rheumatology at the University of Liverpool in the U.K., and colleagues has found anti-drug antibodies (ADAs) in adalimumab- and infliximab-treated patients, but not in etanercept-treated patients. The findings were published online April 27 in Plos One.1

You Might Also Like
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs
  • Anti-TNFs in Early Puberty May Improve Growth in Pediatric IBD
  • Antibodies to Remicade Cross-React with Biosimilar Remsima
Also By This Author
  • Improved Pregnancy Outcomes for Women with SLE

The multi-national study had a cross-sectional design and did not include interventions. It focused on patients with RA who received treatment for 6–24 months and recruited only those who were still responding reasonably well to a given drug treatment and, thus, were still being prescribed that treatment.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

“To our knowledge, this was the first time that [ADA] levels [for] etanercept, adalimumab and infliximab were assessed in a single study using clinical samples from the same patient population, the same methodology, the same laboratory and the same clinical data to evaluate information from a real-world clinical practice setting,” write the authors in their discussion. “This is important to ensure accurate and meaningful comparison of responses [to] the individual therapeutic agents.”

The study included 595 patients (etanercept=200, adalimumab=199 and infliximab=196), all with similar baseline demographics. The mean duration of treatment was 14.6 months (etanercept), 13.5 months (adalimumab) and 13.1 months (infliximab). The treatment doses for all of the drugs were within the approved prescribing ranges.

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Patients tolerated all three TNF inhibitors, and only patients receiving the anti-TNF monoclonal antibodies tested positive for ADA. Although none of the patients treated with etanercept had detectable ADA levels, 24.4% of patients in the pooled adalimumab/infliximab group had detectable ADA levels. Specifically, 31.2% of patients treated with adalimumab and 17.4% of patients treated with infliximab tested positive for ADAs.

When the investigators pooled data from all three TNF inhibitors, they found that 61.1% of patients were in low disease activity (LDA) and 44.1% of patients were in remission. A significantly higher proportion of patients without detectable ADAs (46.7%) than those with detectable ADAs (30.9%) were in remission. Additionally, in the adalimumab- and infliximab-treated groups, patients with detectable ADAs had significantly lower serum trough drug concentrations—80.5% lower in patients treated with adalimumab and 98% lower in patients treated with infliximab. Patients with detectable ADAs also had higher serum levels of the inflammation markers erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP). In addition, the investigators tested composite efficacy measures of Disease Activity Scores (DAS) based on 28-joint count (DAS28) combined with CRP (DAS28-CRP), as well as DAS28-ESR. They found a statistically negative correlation of serum trough drug concentration and these composite efficacy measures, as well as the single efficacy measures of 28 tender joint count, ESR and CRP concentrations in adalimumab-treated patients. Thus, patients without ADAs tended to have a numerically better clinical outcome than those with ADAs.

Pages: 1 2 | Single Page

Filed Under: Conditions, Rheumatoid Arthritis Tagged With: adalimumab, Anti-Drug Antibodies (ADAs), etanercept, infliximab, Rheumatoid Arthritis (RA), TNF inhibitors

You Might Also Like:
  • Infliximab Biosimilar Cross Reacts to Infliximab Antibodies; Plus Treat-to-Target Strategy Promising for Treating RA with bDMARDs
  • Anti-TNFs in Early Puberty May Improve Growth in Pediatric IBD
  • Antibodies to Remicade Cross-React with Biosimilar Remsima
  • The History & Future of Anti-Citrullinated Protein Antibodies (ACPAs)

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2022 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)